1z3n: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1z3n" size="450" color="white" frame="true" align="right" spinBox="true" caption="1z3n, resolution 1.04Å" /> '''Human aldose reduct...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1z3n.gif|left|200px]]<br />
[[Image:1z3n.gif|left|200px]]<br /><applet load="1z3n" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1z3n" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1z3n, resolution 1.04&Aring;" />
caption="1z3n, resolution 1.04&Aring;" />
'''Human aldose reductase in complex with NADP+ and the inhibitor lidorestat at 1.04 angstrom'''<br />
'''Human aldose reductase in complex with NADP+ and the inhibitor lidorestat at 1.04 angstrom'''<br />


==Overview==
==Overview==
Recent efforts to identify treatments for chronic diabetic complications, have resulted in the discovery of a novel series of highly potent and, selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose, reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid, (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while, being 5400 times less active against aldehyde reductase, a related enzyme, involved in the detoxification of reactive aldehydes. It lowers nerve and, lens sorbitol levels with ED(50)'s of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month, diabetic intervention model (1 month of diabetes followed by 2 months of, drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the, motor nerve conduction velocity deficit by 59% relative to diabetic, controls. It has a favorable pharmacokinetic profile (F, 82%; t(1/2), 5.6, h; Vd, 0.694 L/kg) with good drug penetration in target tissues (C(max) in, sciatic nerve and eye are 2.36 and 1.45 mug equiv/g, respectively, when, dosed with [(14)C]lidorestat at 10 mg/kg po).
Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED(50)'s of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t(1/2), 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (C(max) in sciatic nerve and eye are 2.36 and 1.45 mug equiv/g, respectively, when dosed with [(14)C]lidorestat at 10 mg/kg po).


==About this Structure==
==About this Structure==
1Z3N is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with NDP and 3NA as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Aldehyde_reductase Aldehyde reductase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.21 1.1.1.21] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1Z3N OCA].  
1Z3N is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=NDP:'>NDP</scene> and <scene name='pdbligand=3NA:'>3NA</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Aldehyde_reductase Aldehyde reductase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.21 1.1.1.21] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1Z3N OCA].  


==Reference==
==Reference==
Line 15: Line 14:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Dicioccio, A.T.]]
[[Category: Dicioccio, A T.]]
[[Category: Geraci, L.S.]]
[[Category: Geraci, L S.]]
[[Category: Gunn, D.E.]]
[[Category: Gunn, D E.]]
[[Category: Jacot, J.L.]]
[[Category: Jacot, J L.]]
[[Category: Jones, J.H.]]
[[Category: Jones, J H.]]
[[Category: Jones, M.L.]]
[[Category: Jones, M L.]]
[[Category: Mitschler, A.]]
[[Category: Mitschler, A.]]
[[Category: Petrova, T.]]
[[Category: Petrova, T.]]
[[Category: Podjarny, A.D.]]
[[Category: Podjarny, A D.]]
[[Category: Sawicki, D.R.]]
[[Category: Sawicki, D R.]]
[[Category: Sredy, J.]]
[[Category: Sredy, J.]]
[[Category: Zandt, M.C.Van.]]
[[Category: Zandt, M C.Van.]]
[[Category: 3NA]]
[[Category: 3NA]]
[[Category: NDP]]
[[Category: NDP]]
Line 33: Line 32:
[[Category: oxidoreductase]]
[[Category: oxidoreductase]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:28:53 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:11:52 2008''